CORC

在结果中检索

CORC

浏览/检索结果: 共9条，第1-9条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer 期刊论文
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 卷号: 380, 期号: 7
作者:  Wuelfing, P.;  Mano, M. S.;  Loibl, S.;  Mamounas, E. P.;  Untch, M.
收藏  |  浏览/下载：17/0  |  提交时间：2019/12/05
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials 期刊论文
2019, 卷号: 393, 期号: 10179, 页码: 1440-1452
作者:  Boddington, C.;  Bradley, R.;  Braybrooke, J.;  Burrett, J.;  Clarke, M.
收藏  |  浏览/下载：45/0  |  提交时间：2020/01/03
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials 期刊论文
2018, 卷号: 19, 期号: 1, 页码: 27-39
作者:  Alberro, J. A.;  Ballester, B.;  Deulofeu, P.;  Fabregas, R.;  Fraile, M.
收藏  |  浏览/下载：46/0  |  提交时间：2020/01/03
Adjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06) 期刊论文
2017, 卷号: 28
作者:  Lambertini, M.;  Campbell, C.;  Bines, J.;  Korde, L.;  Delso, M. A. Izquierdo
收藏  |  浏览/下载：4/0  |  提交时间：2020/01/03
Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial 期刊论文
2017, 卷号: 35
作者:  Huober, Jens Bodo;  Holmes, Eileen McCormick;  Baselga, Jose
收藏  |  浏览/下载：2/0  |  提交时间：2020/01/04
Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T -> L) or their combination (L plus T) in the adjuvant tre 期刊论文
2017, 卷号: 35
作者:  Moreno-Aspitia, Alvaro;  Holmes, Eileen McCormick;  Jackisch, Christian;  De Azambuja, Evandro;  Boyle, Frances M.
收藏  |  浏览/下载：4/0  |  提交时间：2020/01/04
The impact of early lapatinib-induced rash on disease-free and overall survival in patients treated within the ALTTO phase Ill randomized trial 期刊论文
2016, 卷号: 76
作者:  Azim, H. A., Jr.;  Sonnenblick, A.;  Agbor-Tarh, D.;  Bradbury, I.;  Daly, F.
收藏  |  浏览/下载：3/0  |  提交时间：2020/01/04
DISEASE-FREE SURVIVAL (DFS) IN THE LAPATINIB ALONE ARM AND EXPANDED RESULTS OF THE PHASE III ALTTO TRIAL (BIG 2-06; NCCTG (ALLIANCE) N063D) IN THE ADJUVANT TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER (EBC) 期刊论文
2014, 卷号: 25
作者:  Perez, E. A.;  Holmes, E.;  De Azambuja, E.;  Dueck, A.;  Baselga, J.
收藏  |  浏览/下载：4/0  |  提交时间：2020/01/13
The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 1-06) 期刊论文
2013, 卷号: 73
作者:  Piccart-Gebhart, M.;  Holmes, A. P.;  de Azambuja, E.;  Di Cosimo, S.;  Swaby, R.
收藏  |  浏览/下载：1/0  |  提交时间：2020/01/13

©版权所有 ©2017 CSpace - Powered by CSpace